Art

J-GLOBAL ID：201702266488191927   Reference number：17A1719954

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

局所進行・切除不能または転移性尿路上皮癌(KEYNOTE 052)を用いたシスプラチン安易な患者における第一線pembrolizumab:多施設,単一群,第2相試験【Powered by NICT】

Author (15)： Balar Arjun V (Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY, USA) ,  Castellano Daniel (Hospital Universitario 12 de Octubre (CiberOnc), Madrid, Spain) ,  O'Donnell Peter H (University of Chicago Medical Center, Chicago, IL, USA) ,  Grivas Petros (Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA) ,  Vuky Jacqueline (Oregon Health & Science University, Portland, OR, USA) ,  Powles Thomas (Barts Cancer Institute, Queen Mary University of London, London, UK) ,  Plimack Elizabeth R (Fox Chase Cancer Center, Philadelphia, PA, USA) ,  Hahn Noah M (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA) ,  de Wit Ronald (Erasmus MC Cancer Institute, Rotterdam, Netherlands) ,  Pang Lei (Merck & Co, Kenilworth, NJ, USA) ,  Savage Mary J (Merck & Co, Kenilworth, NJ, USA) ,  Perini Rodolfo F (Merck & Co, Kenilworth, NJ, USA) ,  Keefe Stephen M (Merck & Co, Kenilworth, NJ, USA) ,  Bajorin Dean (Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  Bellmunt Joaquim (Dana-Farber Cancer Institute, Boston, MA, USA)
Material： Lancet Oncology  (Lancet Oncol)
Volume： 18  Issue： 11  Page： 1483-1492  Publication year： 2017 
JST Material Number： W1266A  ISSN： 1470-2045  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Abstract/Point： More than half of all patients...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A1719954&from=J-GLOBAL&jstjournalNo=W1266A") }}

Thesaurus term： *patient ,  elderly person ,  antitumor action ,  evaluation criterion ,  drug therapy ,  *phase 2 study ,  Pneumonia ,  Safety ,  tolerability ,  *Urothelial cancer ,  *platinum complex ,  *antitumor drug ,  *ammine complex ,  *chloro complex ,  adverse reaction
Semi thesaurus term： *cisplatin ,  有害事象 ,  経過観察 ,  完全寛解 ,  全身化学療法 , 【Automatic Indexing@JST】

JST classification (1)： Treatment for tumors in general  (GE03031L)

Terms in the title (6)： 切除不能 ,  転移性尿路上皮癌 ,  シスプラチン ,  患者 ,  施設 ,  第2相試験